Skip to main content
43°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
883.20
-7.48 (-0.84%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation
January 26, 2024
FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients.
Via
Benzinga
Exposures
Product Safety
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.
Via
Benzinga
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
January 23, 2024
Blue-chip healthcare stocks combine stability, profitability, and long-term growth prospects into a single investable package.
Via
InvestorPlace
Momentum Shifts Back To Tech Stocks As Healthcare Lags In 2024
January 22, 2024
Small Cap traders are taking a break in 2024 as XBI is down 2.51% YTD.
Via
Talk Markets
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
January 22, 2024
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape.
Via
Benzinga
Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) qualifies as a quality stock.
January 12, 2024
This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)
Via
Chartmill
Could Regeneron Stock Help You Retire a Millionaire?
January 10, 2024
The blossoming biotech might give more than a nudge to investors in this project.
Via
The Motley Fool
Beyond The Numbers: 13 Analysts Discuss Regeneron Pharmaceuticals Stock
January 09, 2024
Via
Benzinga
2 Smart Growth Stocks to Buy Hand Over Fist in 2024
January 21, 2024
These businesses are on paths to extremely bright futures.
Via
The Motley Fool
EXCLUSIVE: The 'Buy Everything' Market Is Over: Synopsys-Ansys Merger Provides Fertile Ground For This Stock Picker
January 18, 2024
The "buy everything" sentiment that powered equity indices higher last quarter is over. It's a stock picker's market, Marc Chaikin says.
Via
Benzinga
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
January 18, 2024
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Via
Investor's Business Daily
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
January 16, 2024
Biotech stocks are set to rebound in 2024 as the FDA accelerates its approval pace and cash flows back into the industry.
Via
InvestorPlace
Exposures
Product Safety
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
January 12, 2024
The major indexes and leading stocks rebounded. Bitcoin ETFs fell in their debut.
Via
Investor's Business Daily
Topics
ETFs
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
January 05, 2024
Via
Benzinga
Here's Why Regeneron Pharmaceuticals Just Hit A Record High — Again
January 12, 2024
There's more to like about Regeneron Pharmaceuticals than just Eylea, says one analyst.
Via
Investor's Business Daily
Regeneron Pharma's Pipeline Makes This Analyst Turn Bullish
January 12, 2024
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) won a lawsuit last month against Viatris Inc (NASDAQ: VTRS)
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space
January 12, 2024
The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease.
Via
Investor's Business Daily
Regeneron Slumps As Its Biggest Moneymaker Falls Short; Exelixis Dives On Guidance Woes
January 08, 2024
Shares of both skidded early Monday as the annual J.P. Morgan Healthcare Conferenced kicked off In San Francisco.
Via
Investor's Business Daily
3 Top Biotech Stocks Worth Adding To Your Portfolio In 2024
January 07, 2024
Given the continuous need for innovative medical treatments, the biotech industry may be a haven despite its inherent volatility and an uncertain macroeconomic environment. Here are three top biotech...
Via
Talk Markets
How Is The Market Feeling About Regeneron Pharmaceuticals?
December 27, 2023
Via
Benzinga
Unpacking the Latest Options Trading Trends in Regeneron Pharmaceuticals
December 22, 2023
Via
Benzinga
Where Will Regeneron Pharmaceuticals Be in 1 Year?
December 22, 2023
Can the stock continue its market-beating ways?
Via
The Motley Fool
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
January 05, 2024
Shares soared and then tumbled Friday after the company offered $275 million in public shares.
Via
Investor's Business Daily
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
January 05, 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Via
Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
2 Healthcare Stocks That Turned $1,000 Into $2,400 (or More)
January 04, 2024
These innovative biotechs likely aren't done rewarding their shareholders.
Via
The Motley Fool
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
December 28, 2023
Wednesday, a court ruling that found Viatris Inc's (NASDAQ:
Via
Benzinga
Thoughts For Thursday: With War Clouds As A Backdrop The Market Is Set To End The Year On A High
December 28, 2023
The market looks set to end 2023 on a high note, but 2024 is less certain, particularly because though, the US does not want further action in the Gulf, it seems, Iran via its proxies is gaming for...
Via
Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
December 27, 2023
Via
Benzinga
Visualized: The Top S&P 500 Stocks Over 20 Years
December 27, 2023
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.